Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
Luca Cavallone, Adriana Aguilar-Mahecha, Josiane Lafleur...
https://pubmed.ncbi.nlm.nih.gov/32895401/Actively Recruiting
Led by Gene Solutions · Updated on 2025-09-23
125
Participants Needed
3
Research Sites
4 weeks
Total Duration
Researchers are conducting a prospective observational study to evaluate circulating tumor DNA ctDNA levels in female patients diagnosed with stage II-III HER2-positive or triple negative breast cancer who are scheduled for neoadjuvant chemotherapy. The study aims to determine ctDNA detection rates before, during, and after treatment, and to explore how ctDNA levels and MRI imaging relate to pathological complete response pCR following therapy. Participants will undergo neoadjuvant chemotherapy regimens such as AC-T, AC-TH, TCH, or TCHP, with allowance for changes if clinically necessary. Blood samples for ctDNA analysis will be collected at diagnosis, during treatment, and after therapy, alongside tumor tissue samples. Imaging studies including ultrasound, MRI, CT scans, chest x-rays, and PET-CT will be performed throughout to monitor response and compare with ctDNA findings. During the approximately one-year study period, participants will provide demographic and medical history information and attend routine clinical visits where imaging and laboratory tests will be performed. Researchers will assess ctDNA changes and correlate these with MRI results and pCR outcomes to evaluate the prognostic value of combining ctDNA detection and imaging. Safety monitoring and data collection will continue throughout the follow-up.
CONDITIONS
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
L
Lan NL Tu, PHD
V
Van T. Phan, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Gene Solutions
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months following enrollment
Participants have blood samples collected and imaging assessments such as ultrasound, chest x-ray, CT scans, and PET-CT scans during and after neoadjuvant chemotherapy to monitor circulating tumor DNA and treatment response.
Multiple visits aligned with routine clinical care during and post neoadjuvant chemotherapy
Duration - At diagnosis and post-surgery
Participants provide tumor biopsy samples at diagnosis and after surgery for analysis.
2 visits (biopsy at diagnosis and after surgery)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Luca Cavallone, Adriana Aguilar-Mahecha, Josiane Lafleur...
https://pubmed.ncbi.nlm.nih.gov/32895401/Po-Han Lin, Ming-Yang Wang, Chiao Lo...
https://pubmed.ncbi.nlm.nih.gov/34868925/Luca Gianni, Mauro Mansutti, Antonio Anton...
https://pubmed.ncbi.nlm.nih.gov/29327055/Oliver J Stoetzer, Debora M I Fersching, Christoph Salat...
https://pubmed.ncbi.nlm.nih.gov/22983919/E Ortolan, V Appierto, M Silvestri...
https://pubmed.ncbi.nlm.nih.gov/33743331/Chetan Bettegowda, Mark Sausen, Rebecca J Leary...
https://pubmed.ncbi.nlm.nih.gov/24553385/Andreas Schneeweiss, Volker Möbus, Hans Tesch...
https://pubmed.ncbi.nlm.nih.gov/30528802/Frédéric Cailleux, Elisa Agostinetto, Matteo Lambertini...
https://pubmed.ncbi.nlm.nih.gov/36170624/Mark Jesus M Magbanua, Wen Li, Denise M Wolf...
https://pubmed.ncbi.nlm.nih.gov/33767190/A Bottini, A Berruti, M Tampellini...
https://pubmed.ncbi.nlm.nih.gov/9276030/Gene Solutions
Lead Sponsor